ANDRE RUSSOWSKY BRUNONI
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina
413 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 413
- Efficacy of non-invasive brain stimulation in decreasing depression symptoms during the peripartum period: A systematic review(2021) PACHECO, Francisca; GUIOMAR, Raquel; BRUNONI, Andre R.; BUHAGIAR, Rachel; EVAGOROU, Olympia; ROCA-LECUMBERRI, Alba; POLESZCZYK, Anna; BERG, Mijke Lambregtse-van den; CAPARROS-GONZALEZ, Rafael A.; FONSECA, Ana; OSORIO, Ana; SOLIMAN, Mahmoud; AVILA, Ana Ganho-Background: Non-invasive brain stimulation (NIBS) techniques have been suggested as alternative treatments to decrease depression symptoms during the perinatal period. These include brain stimulation techniques that do not require surgery and that are nonpharmacological and non-psychotherapeutic. NIBS with evidence of antidepressant effects include repetitive transcranial magnetic stimulation (rTMS), transcranial electric stimulation (TES) and electroconvulsive therapy (ECT). Objectives: This systematic review aims to summarize evidence on NIBS efficacy, safety and acceptability in treating peripartum depression (PPD). Methods: We included randomized, non-randomized and case reports, that used NIBS during pregnancy and the postpartum. The reduction of depressive symptoms and neonatal safety were the primary and co-primary outcomes, respectively. Results: rTMS shows promising results for the treatment of PPD, with clinically significant decreases in depressive symptoms between baseline and end of treatment and overall good acceptability. Although the safety profile for rTMS is adequate in the postpartum, caution is warranted during pregnancy. In TES, evidence on efficacy derives mostly from single-arm studies, compromising the encouraging findings. Further investigation is necessary concerning ECT, as clinical practice relies on clinical experience and is only described in low-quality case-reports. Limitations: The reduced number of controlled studies, the lack of complete datasets and the serious/high risk of bias of the reports warrant cautious interpretations. Conclusions and implications: Existing evidence is limited across NIBS techniques; comparative studies are lacking, and standard stimulation parameters are yet to be established. Although rTMS benefits from the most robust research, future multicenter randomized clinical trials are needed to determine the position of each NIBS strategy within the pathways of care.
- Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder(2021) SHEPHARD, Elizabeth; STERN, Emily R.; HEUVEL, Odile A. van den; COSTA, Daniel L. C.; BATISTUZZO, Marcelo C.; GODOY, Priscilla B. G.; LOPES, Antonio C.; BRUNONI, Andre R.; HOEXTER, Marcelo Q.; SHAVITT, Roseli G.; REDDY, Y. C. Janardhan; LOCHNER, Christine; STEIN, Dan J.; SIMPSON, H. Blair; MIGUEL, Euripedes C.An important challenge in mental health research is to translate findings from cognitive neuroscience and neuroimaging research into effective treatments that target the neurobiological alterations involved in psychiatric symptoms. To address this challenge, in this review we propose a heuristic neurocircuit-based taxonomy to guide the treatment of obsessive-compulsive disorder (OCD). We do this by integrating information from several sources. First, we provide case vignettes in which patients with OCD describe their symptoms and discuss different clinical profiles in the phenotypic expression of the condition. Second, we link variations in these clinical profiles to underlying neurocircuit dysfunctions, drawing on findings from neuropsychological and neuroimaging studies in OCD. Third, we consider behavioral, pharmacological, and neuromodulatory treatments that could target those specific neurocircuit dysfunctions. Finally, we suggest methods of testing this neurocircuit-based taxonomy as well as important limitations to this approach that should be considered in future research.
- Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates(2023) DINIZ, Elton; FONSECA, Lais; ROCHA, Deyvis; TREVIZOL, Alisson; CERQUEIRA, Raphael; ORTIZ, Bruno; BRUNONI, Andre R.; BRESSAN, Rodrigo; CORRELL, Christoph U.; GADELHA, AryObjective: To define the prevalence and correlates of treatment-resistant schizophrenia (TRS) through a systematic review and meta-analysis.Methods: Following PRISMA criteria, an electronic search was performed in PubMed and EMBASE through May 17, 2022. All study designs that assessed a minimum of 20 schizophrenia-spectrum patients, providing data on TRS prevalence or allowing its calculation, were included. Estimates were produced using a random-effects model meta-analysis.Results: The TRS prevalence across 50 studies (n=29,390 subjects, mean age=383 +/- 62 years, males=648 +/- 121%, mean illness duration=143 +/- 53 years) was 36.7% (95%CI=33.1-40.5%; I2=97.3%, p<0.0001). The prevalence ranged from 22% (95%CI=18.4-25.8%) in first-episode to 39.5% (95%CI=32.2-47.0%) in multiple-episode samples (Q=18.27, p<0.0001). Primary treatment resistance was 23.6% (95%CI=205-268%) vs. 9.3% (95%CI=68-122) for later-onset/secondary (>= 6 months after initial treatment response). Longer illness duration and recruitment from long-term hospitals or clozapine clinics were associated with higher prevalence estimates. In meta-regression analyses, older age and poor functioning predicted greater TRS. When including only studies with lower bias risk, the TRS prevalence was 28.4%.Conclusions: Different study designs and recruitment strategies accounted for most of the observed heterogeneity in TRS prevalence rates. The results point to early-onset and later-onset TRS as two separate disease pathways requiring clinical attention.
- Imaging genetics paradigms in depression research: Systematic review and meta-analysis(2018) PEREIRA, Licia P.; KOHLER, Cristiano A.; STUBBSB, Brendon; MISKOWIAK, Kamilla W.; MORRIS, Gerwyn; FREITAS, Barbara P. de; THOMPSON, Trevor; FERNANDES, Brisa S.; BRUNONI, Andre R.; MAES, Michael; PIZZAGALLI, Diego A.; CARVALHO, Andre F.Imaging genetics studies involving participants with major depressive disorder (MDD) have expanded. Nevertheless, findings have been inconsistent. Thus, we conducted a systematic review and meta-analysis of imaging genetics studies that enrolled MDD participants across major databases through June 30th, 2017. Sixty-five studies met eligibility criteria (N = 4034 MDD participants and 3293 controls), and there was substantial between-study variability in the methodological quality of included studies. However, few replicated findings emerged from this literature with only 22 studies providing data for meta-analyses (882 participants with MDD and 616 controls). Total hippocampal volumes did not significantly vary in MDD participants or controls carrying either the BDNF Val66Met 'Met' (386 participants with MDD and 376 controls) or the 5-HTTLPR short 'S' (310 participants with MDD and 230 controls) risk alleles compared to non-carriers. Heterogeneity across studies was explored through meta-regression and subgroup analyses. Gender distribution, the use of medications, segmentation methods used to measure the hippocampus, and age emerged as potential sources of heterogeneity across studies that assessed the association of 5-HTTLPR short 'S' alleles and hippocampal volumes. Our data also suggest that the methodological quality of included studies, publication year, and the inclusion of brain volume as a covariate contributed to the heterogeneity of studies that assessed the association of the BDNF Val66Met 'Met' risk allele and hippocampal volumes. In exploratory voxel-wise meta-analyses, MDD participants carrying the 5-HTTLPR short 'S' allele had white matter microstructural abnormalities predominantly in the corpus callosum, while carriers of the BDNF Val66Met 'Met' allele had larger gray matter volumes and hyperactivation of the right middle frontal gyrus compared to non-carriers. In conclusion, few replicated findings emerged from imaging genetics studies that included participants with MDD. Nevertheless, we explored and identified specific sources of heterogeneity across studies, which could provide insights to enhance the reproducibility of this emerging field.
- Is dynapenia associated with the onset and persistence of depressive and anxiety symptoms among older adults? Findings from the Irish longitudinal study on ageing(2021) CARVALHO, Andre F.; MAES, Michael; SOLMI, Marco; BRUNONI, Andre R.; LANGE, Shannon; HUSAIN, M. Ishrat; KURDYAK, Paul; REHM, Jurgen; KOYANAGI, AiObjectives: The aim of the current study was to assess the associations between dynapenia and the onset and persistence of depression and anxiety among older adults. Methods: This prospective cohort study enrolled community-living older adults (N = 5271; 51.1% females) aged >= 50 years (mean age = 63.2, standard deviation = 9.0) from The Irish Longitudinal Study on Aging (TILDA), Ireland. At baseline, participants completed a handgrip assessment. Depression was defined by a score >= 16 in the Center of Epidemiology Studies Depression (CES-D) tool and anxiety was considered when participants scored >= 8 on the anxiety section of the Hospital Anxiety and Depression Scale (HADS). Outcomes were incident and persistent depression and anxiety at two years follow-up. Multivariable logistic regression models were built for each outcome. Results: After controlling for age, sex, education, marital status, employment status, smoking, body mass index, number of chronic conditions, physical activity, and cognitive function, low handgrip strength indicative of dyapenia (< 30 Kg for men and < 20 Kg for women) was associated with a greater likelihood for incident depressive (OR = 1.44; 95%CI: 1.08-1.92) as well as for persistent depressive (OR = 1.61; 95% CI: 1.01-2.58) and anxiety (OR = 1.61; 95% CI: 1.20-2.14) symptoms. Conclusions: Dynapenia was associated with a higher odds of developing depressive symptoms as well as a greater likelihood to persistent depressive and anxiety symptoms among older adults. Our data suggest that interventions targeting muscle strength may prevent the onset of late-life depression and also may hold promise as novel therapeutic opportunities for depression and anxiety in later life.
- tDCS as an Add-on Therapy: The Augmentative Role of tDCS for the Treatment of Depression(2014) BRUNONI, Andre
- Primum non nocere or primum facere meliorem? Hacking the brain in the 21st century(2017) BORRIONE, Lucas; BRUNONI, Andre R.Abstract Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that modulates cortical excitability. It is devoid of serious adverse events and exerts variable effects on cognition, with several research findings suggesting that it can improve memory, verbal and mathematical skills. Because tDCS devices are low-cost, portable and relatively easy to assemble, they have become available outside of the medical setting and used for non-medical (“cosmetic”) purposes by laypersons. In this sense, tDCS has become a popular technique aiming to improve cognition and the achievement of a better performance not only at work, but also in other fields such as sports, leisure activities (video games) and even the military. In spite of these unforeseen developments, there has been a general paralysis of the medical and regulatory agencies to develop guidelines for the use of tDCS for cosmetic purposes. Several challenges are present, most importantly, how to restrict tDCS use outside of the medical setting in face of variable and sometimes conflicting results from scientific research. This article aims to describe the popular use of tDCS, in light of the pillars of neuroethics, a branch of bioethics relative to brain research. Between two possible but extreme solutions – total release or total restriction of tDCS – it is paramount to develop a spectrum of alternatives, which may vary over time and in different cultural backgrounds.
conferenceObject EFFICACY AND SAFETY OF TRANSCRANIAL DIRECT CURRENT STIMULATION FOR TREATING NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: THE FOLLOW-UP PHASE(2020) VALIENGO, Leandro; SERPA, Mauricio; ELKIS, Helio; BILT, Martinus Van de; LACERDA, Acioly; GATTAZ, Wagner; BRUNONI, Andrearticle 46 Citação(ões) na Scopus Manic Psychosis After Sertraline and Transcranial Direct-Current Stimulation(2011) BRUNONI, Andre Russowsky; VALIENGO, Leandro; ZANAO, Tamires; OLIVEIRA, Janaina Farias de; BENSENOR, Isabela Martins; FREGNI, Felipe- Changes in motor cortical excitability in schizophrenia following transcranial direct current stimulation(2019) GORDON, Pedro Caldana; VALIENGO, Leandro da Costa Lane; PAULA, Vanessa Jesus Rodrigues de; GALHARDONI, Ricardo; ZIEMANN, Ulf; ANDRADE, Daniel Ciampi de; BRUNONI, Andre RussowskySchizophrenia is a disorder associated with cortical inhibition deficits. Transcranial direct current stimulation (tDCS) induces changes in cortical excitability in healthy subjects and individuals with neuropsychiatric disorders depending on the stimulation parameters. Our aim was to investigate whether a previously published tDCS protocol associated with symptomatic improvement in schizophrenia would induce changes in motor cortical excitability, assessed by transcranial magnetic stimulation paradigms, i.e., short-interval intracortical inhibition (SICI) and intra-cortical facilitation (ICF). We assessed cortical excitability measurements in 48 subjects with schizophrenia before and after a single session of active tDCS (20 min, 2 mA, anode over left dorsolateral prefrontal cortex, cathode over left temporoparietal cortex) or sham. Those who received active tDCS had a significant increase of SICI in the left motor cortex compared to those who received sham stimulation (Cohen's d = 0.54, p = .019). No changes were observed for ICF. In addition, lower SICI was associated with higher age (beta = -0.448, p < .01). Increase in intracortical inhibition may indicate a mechanism of action of tDCS in this population. Future studies should investigate whether this finding is a biomarker of treatment response for schizophrenia.